BrainsWay (BWAY) details first coverage policy for Accelerated Deep TMS in 6-K filing

Rhea-AI Filing Summary

BrainsWay Ltd. submitted a Form 6-K as a foreign private issuer, linking it to its existing Form S-8 and Form F-3 registration statements. The filing mainly furnishes an exhibit titled “BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™”, indicating a new coverage policy related to its Accelerated Deep TMS treatment. The report was signed by the company’s Chief Executive Officer, Hadar Levy.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-35165

BRAINSWAY LTD.
(Translation of registrant's name into English)

16 Hartum Street RAD Tower, 14th Floor
Har HaHotzvim
Jerusalem, 9777516, Israel
(+972-2) 582-4030
 (Address and telephone number of Registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 22, 2019 (Registration No. 333- 230979) and the Company's Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 22, 2024 (Registration No. 333-280934) and on April 22, 2025 (Registration No. 333-286672).

EXHIBIT INDEX

Exhibit		Title
99.1		BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		BRAINSWAY LTD.
		(Registrant)
Date: January 7, 2026		/s/ Hadar Levy
		Hadar Levy
		Chief Executive Officer

FAQ

What did BrainsWay Ltd. (BWAY) file in this Form 6-K?

BrainsWay Ltd. filed a Form 6-K report as a foreign private issuer, primarily to furnish an exhibit concerning a new coverage policy for its Accelerated Deep TMS™ treatment.

What key exhibit is included in BrainsWay (BWAY) January 2026 Form 6-K?

The Form 6-K includes Exhibit 99.1, titled “BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™”, which reflects a new coverage policy related to that treatment.

Does the BrainsWay (BWAY) Form 6-K relate to any existing registration statements?

Yes. The Form 6-K is incorporated by reference into BrainsWay’s Form S-8 from April 22, 2019 and its Form F-3 registration statements filed on July 22, 2024 and April 22, 2025.

Who signed the BrainsWay Ltd. (BWAY) January 2026 Form 6-K?

The report was signed on behalf of BrainsWay Ltd. by Hadar Levy, the company’s Chief Executive Officer, dated January 7, 2026.

What does the coverage policy mentioned by BrainsWay (BWAY) involve?

The exhibit title indicates a first coverage policy for Accelerated Deep TMS™. Specific terms or parties involved are not detailed in the provided text.

What reporting form does BrainsWay Ltd. (BWAY) use for its annual reports?

The company indicates that it files its annual reports under cover of Form 20-F, consistent with its status as a foreign private issuer.